Eli Lilly Launches RET-Targeted Cancer Drug Tanstrive in India
Eli Lilly and Company India has launched Tanstrive, an oral cancer drug targeting RET gene alterations in patients with locally advanced or metastatic solid tumours. Approved by the Central Drugs Standard Control Organisation (CDSCO), Tanstrive is available in 40 mg to 160 mg tablets, administered twice daily. Priced at Rs 2.15 lakh per box for a 14-day regimen, the drug aims to expand access to precision oncology treatments in India, addressing cancers driven by RET mutations, including lung and thyroid cancers.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 32/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- mint— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
- news18— balanced framing, positive sentiment
AI Analysis
The articles primarily present a corporate and regulatory perspective, focusing on the drug launch and approval by Indian authorities. There is no evident political framing or partisan viewpoints; coverage centers on medical and business aspects, reflecting industry and regulatory stakeholders without political commentary or critique.
The overall tone across the articles is neutral to positive, emphasizing the advancement in cancer treatment and expanded patient access. The language highlights the drug's targeted approach and regulatory approval without sensationalism or criticism, maintaining an informative and factual tone.
How 3 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.